BSL

Basilea Pharmace

Stock
Stock
ISIN: CH0011432447
Ticker: BSLN
CH0011432447
BSLN

Price

Price

CHART BY

Historical dividends and forecast

 


$0.383

CHART BY

Frequently asked questions

The market capitalization of Basilea Pharmace is $1.11B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Basilea Pharmace is 17.35. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Basilea Pharmace's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $5.167. EPS indicates the company's profitability on a per-share basis.
Currently, 5 analysts cover Basilea Pharmace's stock, with a consensus target price of $105.78. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Basilea Pharmace reported a revenue of $300.98M.
Basilea Pharmace's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $77.41M. EBITDA measures the company's overall financial performance.
Basilea Pharmace has a free cash flow of $67.27M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Basilea Pharmace employs approximately 189 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Basilea Pharmace is 11.41M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$1.11B
EPS (TTM) 
$5.167
Free Float 
11.41M
P/E ratio (TTM) 
17.35
Revenue (TTM) 
$300.98M
EBITDA (TTM) 
$77.41M
Free Cashflow (TTM) 
$67.27M

Pricing

1D span
$86.34$89.11
52W span
$55.45$91.45

Analyst Ratings

The price target is $105.78 and the stock is covered by 5 analysts.

Buy

3

Hold

2

Sell

0

Information

Basilea Pharmaceutica AG engages in the discovery, development, and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000 and is headquartered in Allschwil, Switzerland.

Employees
189
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

ISIN
CH0011432447
Primary Ticker
BSLN

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation